Business Context and Reporting Period
Legend Biotech Corporation, a foreign private issuer, filed Form 6-K on June 22, 2026, to disclose a corporate financing event. The report details an underwritten public offering of American Depositary Shares (ADSs) entered into on June 17, 2026, with an expected closing date of June 23, 2026.
Key Financial Metrics
This filing describes a capital raise rather than operational performance; therefore, revenue, profit, cash flow, margins, and debt metrics are not reported in this document.
- Shares Offered: 7,700,000 ADSs (representing 15,400,000 ordinary shares).
- Offering Price: $29.35 per ADS.
- Expected Net Proceeds: Approximately $211.6 million (excluding underwriting discounts, commissions, and offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,155,000 additional ADSs.
Material Changes
The filing does not provide comparative financial data or operational changes versus prior periods. The primary material change is the execution of the Underwriting Agreement and the anticipated increase in cash liquidity upon the closing of the Offering.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on operational outlook, or specific risk factors beyond standard underwriting terms. The Offering is subject to customary closing conditions. The Underwriting Agreement includes customary representations, warranties, covenants, and indemnification obligations.
Investor Verification Checklist
- Verify the final closing date of the Offering, currently expected on or about June 23, 2026.
- Confirm whether the underwriters exercise the 30-day option to purchase the additional 1,155,000 ADSs.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific termination provisions and indemnification details.
- Check the press release (Exhibit 99.1) for any additional context on the use of proceeds not detailed in the summary.